ArticleRenal failure2024
Employing urinary biomarkers to infer the absence of acute kidney disease in outpatients with a single serum creatinine measurement.
Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Employing urinary biomarkers in predicting renal recovery three months after in-hospital acute kidney injury.Renal failure · 2025Article
- Reference intervals for urine creatinine-to-specific gravity ratio as an indicator of relative creatinine excretion rate: a cross-sectional study.Annals of medicine and surgery (2012) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionIn outpatient settings, it is challenging to exclude acute kidney disease (AKD) based on a single serum creatinine (SCr) measurement. This retrospective study aimed to explore the usefulness of urinary biomarkers and a novel functional biomarker, a spot urine creatinine-to-osmolality ratio (sUCr/Osm), for inferring the absence of AKD.
methodsThe cohort was from the ASSESS-AKI Study. 'No AKD' was defined as the absence of a SCr increase ≥ 26.5 μmol/L between the preceding visit and the index visit, with a three-month interval. Urinary neutrophil gelatinase-associated lipocalin (UNGAL) was selected as the representative biomarker out of six known candidates. UNGAL levels < 100 ng/mL indicated a positive test. sUCr/Osm values ≥ 7.07 indicated a positive test.
resultsOf the 1,570 participants, 38.0% were female. The mean age (mean ± SD) was 64.6 ± 13.0 years, and the mean SCr level was 102.5 ± 51.4 μmol/L. The area under the receiver operating characteristic curve for UNGAL in identifying 'No AKD' for all participants was 0.548 (95% confidence interval: 0.495-0.600), whereas that for sUCr/Osm was 0.578 (0.525-0.630). The sensitivity of UNGAL was 0.867 (0.849-0.884), with a positive predictive value of 0.917 (0.902-0.932) and an accuracy of 0.808 (0.788-0.827). The corresponding values of sUCr/Osm were 0.926 (0.912-0.939), 0.906 (0.891-0.921), and 0.845 (0.827-0.863). In individuals whose SCr-derived estimated glomerular filtration rate was < 60 mL/min/1.73 m
conclusionUsing sUCr/Osm to infer the absence of AKD in outpatients with a single SCr measurement may be as effective as using UNGAL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.